PPIL3 and neoplasm: Given that previous studies have found that PPIL3 has the lowest risk ratio in the model and that its expression in tumor tissue is lower than that in adjacent normal tissue, both in the immunotherapy response group and the immunotherapy non-response group, we further explored the effect of its expression on Bca cell lines in in vitro experiments.